Growth Hormone Improves Social Impairments From Autism Linked Disorder
New research has found that a growth hormone can significantly improve the social impairment associated with autism spectrum disorder (ASD) in patients with a related genetic syndrome. The pilot study, conducted at the Icahn School of Medicine at Mount Sinai, focused on the use of insulin-like growth factor-1 (IGF-1) to treat Phelan-McDermid syndrome (PMS), a disorder caused by a deletion or mutation of the SHANK3 gene on chromosome 22. “Ours is the first controlled trial of any treatment for Phelan-McDermid syndrome,” said Alexander Kolevzon, MD, clinical director of the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai.
- Dr. Alexander Kolevzon, Associate Professor, Psychiatry, Pediatrics, Clinical Director, the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai
Additional Coverage:
Business Standard
News-Medical
Medical Xpress
Zee News
Mount Sinai Health System to Roll Out Microsoft Dragon Copilot
Nov 05, 2025 View All Press Releases
NIH Awards $10 Million for the New York Regional Diabetes Research Center
Oct 23, 2025 View All Press Releases
